Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies

Journal of Medicinal Chemistry

Volumn 59, Issue 18, 2016, Pages 8412-8421

  Denèfle, Thomas ^a,b   Boullet, Héloise ^a,b   Herbi, Linda ^a,c,d   Newton, Clara ^a,b   Martinez Torres, Ana Carolina ^a,c,d   Guez, Alexandre ^a,b   Pramil, Elodie ^a,b,c,d   Quiney, Claire ^a,c,d   Pourcelot, Marilyne ^a,b   Levasseur, Mikail D ^a,b   Lardé, Eva ^a,b   Moumné, Roba ^a,b   Ogi, François Xavier ^f   Grondin, Pascal ^g   Merle Beral, Hélène ^a,c,e   Lequin, Olivier ^a,b   Susin, Santos A ^a,c,d   Karoyan, Philippe ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ECOLE NORMALE SUPÉRIEURE   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f NanoTemper Technologies GmbH   (Germany)

^g GSK   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PEPTIDOMIMETIC AGENT; THROMBOSPONDIN 1 MIMETIC AGONIST PEPTIDE; UNCLASSIFIED DRUG; PEPTIDE; THROMBOSPONDIN 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CIRCULAR DICHROISM; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MASS SPECTROMETRY; NITROGEN NUCLEAR MAGNETIC RESONANCE; PEPTIDE SYNTHESIS; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; AGONISTS; AMINO ACID SEQUENCE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR MODEL; NEOPLASMS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSPONDIN 1;

EID: 84988735397     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00781     Document Type: Article

References (50)

1. Biemar, F.; Foti, M. Global progress against cancer-challenges and opportunities Cancer Biol. Med. 2013, 10, 183-186 10.7497/j.issn.2095-3941.2013.04.001
2. World Cancer Research Fund International (WCRFI). Worldwide data. http://www.wcrf.org/int/cancer-facts-figures/worldwide-data (accessed July 14, 2016).
3. Favaloro, B.; Allocati, N.; Graziano, V.; Di Ilio, C.; De Laurenzi, V. Role of apoptosis in disease Aging 2012, 4, 330-349 10.18632/aging.100459
4. Lobo, I. Chromosome abnormalities and cancer cytogenetics Nat. Educ. 2008, 1 (1) 68
5. Calin, G. A.; Croce, C. M. MicroRNAs and chromosomal abnormalities in cancer cells Oncogene 2006, 25, 6202-6210 10.1038/sj.onc.1209910
6. For more information see the following: http://cgap.nci.nih.gov/Chromosomes/Mitelman (accessed May, 20, 2016).
7. Secchiero, P.; di Iasio, M. G.; Gonelli, A.; Zauli, G. The MDM2 inhibitor nutlins as an innovative therapeutic tool for the treatment of haematological malignancies Curr. Pharm. Des. 2008, 14, 2100-2110 10.2174/138161208785294663
8. Gandhi, L.; Camidge, D. R.; de Oliveira, M. R.; Bonomi, P.; Gandara, D.; Khaira, D.; Hann, C. L.; McKeegan, E. M.; Litvinovich, E.; Hemken, P. M.; Dive, C.; Enschede, S. H.; Nolan, C.; Chiu, Y.-L.; Busman, T.; Xiong, H.; Krivoshik, A. P.; Humerickhouse, R. H.; Shapiro, G. I.; Rudin, C. M. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors J. Clin. Oncol. 2011, 29, 909-916 10.1200/JCO.2010.31.6208
9. Sun, H.; Nikolovska-Coleska, Z.; Yang, C.-H.; Qian, D.; Lu, J.; Qiu, S.; Bai, L.; Peng, Y.; Cai, Q.; Wang, S. Design of Small-Molecule Peptidic and Non-Peptidic Smac Mimetics Acc. Chem. Res. 2008, 41, 1264-1277 10.1021/ar8000553
10. Murray, J. K.; Gellman, S. H. Targeting protein-protein interactions: lessons from p53/MDM2 Biopolymers 2007, 88, 657-686 10.1002/bip.20741
11. Chang, Y. S.; Graves, B.; Guerlavais, V.; Tovar, C.; Packman, K.; To, K.-H.; Olson, K. A.; Kesavan, K.; Gangurde, P.; Mukherjee, A.; Baker, T.; Darlak, K.; Elkin, C.; Filipovic, Z.; Qureshi, F. Z.; Cai, H.; Berry, P.; Feyfant, E.; Shi, X. E.; Horstick, J.; Annis, D. A.; Manning, A. M.; Fotouhi, N.; Nash, H.; Vassilev, L. T.; Sawyer, T. L. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 3445-3454 10.1073/pnas.1303002110
12. Dohner, H.; Stilgenbauer, S.; Benner, A.; Leupolt, E.; Kröber, A.; Bullinger, L.; Döhner, K.; Bentz, M.; Lichter, P. Genomic aberrations and survival in chronic lymphocytic leukemia N. Engl. J. Med. 2000, 343, 1910-1916 10.1056/NEJM200012283432602
13. Gilead. Direct Healthcare Professional Communication. https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information - -zydelig-%28idelalisib%29.pdf?sfvrsn=0 (accessed May, 20, 2016).
14. Smolej, L.; Šimkovič, M. Practical approach to management of chronic lymphocytic leukemia Arch. Med. Sci. 2016, 12, 448-456 10.5114/aoms.2016.55424
15. Wilson, F. H.; Johannessen, C. M.; Piccioni, F.; Tamayo, P.; Kim, J. W.; Van Allen, E. M.; Corsello, S. M.; Capelletti, M.; Calles, A.; Butaney, M.; Sharifnia, T.; Gabriel, S. B.; Mesirov, J. P.; Hahn, W. C.; Engelman, J. A.; Meyerson, M.; Root, D. E.; Jänne, P. A.; Garraway, L. A. A functional landscape of resistance to ALK inhibition in lung cancer Cancer Cell 2015, 27, 397-408 10.1016/j.ccell.2015.02.005
16. Henkin, J.; Volpert, O. V. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1 Expert Opin. Ther. Targets 2011, 15, 1369-1386 10.1517/14728222.2011.640319
17. Jeanne, A.; Schneider, C.; Martiny, L.; Dedieu, S. Original insights on thrombospondin-1-related antireceptor strategies in cancer Front. Pharmacol. 2015, 6, 1-13 10.3389/fphar.2015.00252
18. Kosfeld, M. D.; Frazier, W. A. Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal binding domain of human thrombospondin J. Biol. Chem. 1993, 268, 8808-8814
19. Gao, A.-G.; Frazier, W. A. Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins J. Biol. Chem. 1994, 269, 29650-29657
20. Gao, A. G.; Lindberg, F. B.; Finn, M. B.; Blystone, S. D.; Brown, E. J.; Frazier, W. A. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin J. Biol. Chem. 1996, 271, 21-24 10.1074/jbc.271.1.21
21. Kaur, S.; Soto-Pantoja, D. R.; Stein, E. V.; Liu, C.; Elkahloun, A. G.; Pendrak, M. L.; Nicolae, A.; Singh, S. P.; Nie, Z.; Levens, D.; Isenberg, J. S.; Roberts, D. D. Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors Sci. Rep. 2013, 3, 1673-1711 10.1038/srep01673
22. Miller, T. W.; Kaur, S.; Ivins-O'Keefe, K.; Roberts, D. D. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation Matrix Biol. 2013, 32, 316-324 10.1016/j.matbio.2013.02.009
23. Roberts, D. D.; Kaur, S.; Soto-Pantoja, D. R. Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer J. Cell Commun. Signal. 2015, 9, 101-102 10.1007/s12079-015-0283-9
24. Floquet, N.; Dedieu, S.; Martiny, L.; Dauchez, M.; Perahia, D. Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: A molecular modeling study Arch. Biochem. Biophys. 2008, 478, 103-109 10.1016/j.abb.2008.07.015
25. Kaur, S.; Martin-Manso, G.; Pendrak, M. L.; Garfield, S. H.; Isenberg, J. S.; Roberts, D. D. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47 J. Biol. Chem. 2010, 285, 38923-38932 10.1074/jbc.M110.172304
26. Mateo, V.; Lagneaux, L.; Bron, D.; Biron, G.; Armant, M.; Delespesse, G.; Sarfati, M. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia Nat. Med. 1999, 5, 1277-1284 10.1038/15233
27. Johansson, U.; Higginbottom, K.; Londei, M. CD47 ligation induces a rapid caspase- independent apoptosis-like cell death in human monocytes and dendritic cells Scand. J. Immunol. 2004, 59, 40-49 10.1111/j.0300-9475.2004.01355.x
28. Miyata, Y.; Watanabe, S.; Kanetake, H.; Sakai, H. Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract BMC Cancer 2012, 12, 372 10.1186/1471-2407-12-372
29. Manna, P. P.; Frazier, W. A. The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A J. Immunol. 2003, 170, 3544-3553 10.4049/jimmunol.170.7.3544
30. Teuchert, M.; Berghöfer, S.; Klenk, H.-D.; Garten, W. Recycling of furin from the plasma membrane J. Biol. Chem. 1999, 274, 36781-36789 10.1074/jbc.274.51.36781
31. Henrich, S.; Cameron, A.; Bourenkov, G. P.; Kiefersauer, R.; Huber, R.; Lindberg, I.; Bode, W.; Than, M. E. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity Nat. Struct. Biol. 2003, 10, 520-526 10.1038/nsb941
32. Moumne, R.; Larregola, M.; Boutadla, Y.; Lavielle, S.; Karoyan, P. Aminomethylation of chiral silyl enol ethers: access to beta(2)-homotryptophane and beta(2)-homolysine derivatives Tetrahedron Lett. 2008, 49, 4704-4707 10.1016/j.tetlet.2008.05.131
33. Moumne, R.; Denise, B.; Guitot, K.; Rudler, H.; Lavielle, S.; Karoyan, P. New scalable asymmetric aminomethylation reaction for the synthesis of beta(2)-amino acids Eur. J. Org. Chem. 2007, 2007 (12) 1912-1920 10.1002/ejoc.200600926
34. Lukaszuk, A.; Demaegdt, H.; Szemenyei, E.; Toth, G.; Tymecka, D.; Misicka, A.; Karoyan, P.; Vanderheyden, P.; Vauquelin, G.; Tourwe, D. Beta-homo-amino acid scan of angiotensin IV J. Med. Chem. 2008, 51, 2291-2296 10.1021/jm701490g
35. Avbelj, F.; Grdadolnik, S. G.; Grdadolnik, J.; Baldwin, R. L. Intrinsic backbone preferences are fully present in blocked amino acids Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1272-1277 10.1073/pnas.0510420103
36. a) coupling constants in 15N-enriched proteins J. Am. Chem. Soc. 1993, 115, 7772-7777 10.1021/ja00070a024
37. Rebres, R. A.; Vaz, L. E.; Green, J. M.; Brown, E. J. Normal ligand binding and signaling by CD47 (integrin-associated protein) requires a long range disulfide bond between the extracellular and membrane-spanning domains J. Biol. Chem. 2001, 276, 34607-34616 10.1074/jbc.M106107200
38. Martinez-Torres, A.-C.; Quiney, C.; Attout, T.; Boullet, H.; Herbi, L.; Vela, L.; Barbier, S.; Chateau, D.; Chapiro, E.; Nguyen-Khac, F.; Davi, F.; Le Garff-Tavernier, M.; Moumné, R.; Sarfati, M.; Karoyan, P.; Merle-Béral, H.; Launay, P.; Susin, S. A. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans PLoS Med. 2015, 12 (3) e1001796 10.1371/journal.pmed.1001796
39. McDonald, J. F.; Dimitry, J. M.; Frazier, W. A. An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM Motifs Biochemistry 2003, 42, 10001-10011 10.1021/bi0341408
40. Sagan, S.; Karoyan, P.; Chassaing, G.; Lavielle, S. Further delineation of the two binding sites associated with Tachykinin Neurokinin-1 receptors using [3-Prolinomethionine11]SP analogues J. Biol. Chem. 1999, 274, 23770-23776 10.1074/jbc.274.34.23770
41. Galluzzi, L.; Bravo-San Pedro, J. M.; Vitale, I.; Aaronson, S. A.; Abrams, J. M.; Adam, D.; Kroemer, G. Essential versus accessory aspects of cell death: recommendations of the NCCD Cell Death Differ. 2015, 22 (1) 58-73 10.1038/cdd.2014.137
42. Karoyan, P.; Launay, P.; Merle-Beral, H.; Susin, S. A. Method and pharmaceutical composition for use in the treatment of cancer. WO 2013182650 A1, 2013.
43. Moumne, R.; Denise, B.; Parlier, A.; Lavielle, S.; Rudler, H.; Karoyan, P. One-pot synthesis of β-amino acid derivatives via addition of bis(O-silyl) ketene acetals on iminium salts Tetrahedron Lett. 2007, 48, 8277-8280 10.1016/j.tetlet.2007.09.119
44. Moumne, R.; Denise, B.; Guitot, K.; Rudler, H.; Lavielle, S.; Karoyan, P. New scalable asymmetric aminomethylation reaction for the synthesis of β2-amino acids Eur. J. Org. Chem. 2007, 2007 (12) 1912-1920 10.1002/ejoc.200600926
45. Goddard, T. D.; Kneller, D. G. Sparky, version 3; University of California: San Francisco, CA; http://www.cgl.ucsf.edu/home/sparky/ (accessed May, 20, 2016).
46. Kvansakul, M.; Adams, J. C.; Hohenester, E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats EMBO J. 2004, 23, 1223-1233 10.1038/sj.emboj.7600166
47. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291 10.1107/S0021889892009944
48. Han, B.; Liu, Y.; Ginzinger, S.; Wishart, D. SHIFTX2: significantly improved protein chemical shift prediction J. Biomol. NMR 2011, 50, 43-57 10.1007/s10858-011-9478-4
49. Jerabek-Willemsen, M.; Wienken, C. J.; Braun, D.; Baaske, P.; Duhr, S. Molecular interaction studies using microscale thermophoresis Assay Drug Dev. Technol. 2011, 9, 342-353 10.1089/adt.2011.0380
50. Monolith NT Protein Labeling Kit RED-NHS. User Manual. http://www.helsinki.fi/biosciences/corefacilities/microscalethermophoresis/Protein-Labeling-Manual-V012-RED-NHS.pdf (accessed May, 20, 2016).